IDR 400.0
(-1.48%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 127.06 Billion IDR | -20.19% |
2022 | 159.21 Billion IDR | -32.54% |
2021 | 236.01 Billion IDR | 96.0% |
2020 | 120.41 Billion IDR | 102.07% |
2019 | 59.59 Billion IDR | 6.38% |
2018 | 56.02 Billion IDR | 26.96% |
2017 | 44.12 Billion IDR | 1539.06% |
2016 | 2.69 Billion IDR | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q3 | 49.88 Billion IDR | 37.87% |
2024 Q1 | 27.57 Billion IDR | -52.82% |
2024 Q2 | 37.73 Billion IDR | 36.86% |
2023 Q2 | 29.08 Billion IDR | 39.57% |
2023 FY | 127.06 Billion IDR | -20.19% |
2023 Q3 | 20.33 Billion IDR | -30.09% |
2023 Q4 | 58.44 Billion IDR | 187.42% |
2023 Q1 | 20.83 Billion IDR | -62.06% |
2022 FY | 159.21 Billion IDR | -32.54% |
2022 Q4 | 54.93 Billion IDR | 128.47% |
2022 Q3 | 24.04 Billion IDR | -32.25% |
2022 Q2 | 35.48 Billion IDR | -20.7% |
2022 Q1 | 44.74 Billion IDR | -6.68% |
2021 Q1 | 38.89 Billion IDR | -59.16% |
2021 FY | 236.01 Billion IDR | 96.0% |
2021 Q4 | 47.95 Billion IDR | -42.11% |
2021 Q3 | 82.83 Billion IDR | 24.86% |
2021 Q2 | 66.33 Billion IDR | 70.55% |
2020 Q2 | 6.37 Billion IDR | 13.92% |
2020 Q1 | 5.6 Billion IDR | -85.11% |
2020 FY | 120.41 Billion IDR | 102.07% |
2020 Q4 | 95.23 Billion IDR | 621.45% |
2020 Q3 | 13.2 Billion IDR | 106.91% |
2019 Q2 | 7.45 Billion IDR | 35.6% |
2019 FY | 59.59 Billion IDR | 6.38% |
2019 Q1 | 5.49 Billion IDR | 0.0% |
2019 Q3 | 9.03 Billion IDR | 21.14% |
2019 Q4 | 37.6 Billion IDR | 316.46% |
2018 Q1 | 8.76 Billion IDR | 0.0% |
2018 FY | 56.02 Billion IDR | 26.96% |
2017 FY | 44.12 Billion IDR | 1539.06% |
2016 FY | 2.69 Billion IDR | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
PT Enseval Putera Megatrading Tbk. | 2913.35 Billion IDR | 95.639% |
PT Kimia Farma (Persero) Tbk | 2780.27 Billion IDR | 95.43% |
PT Millennium Pharmacon International Tbk | 273.37 Billion IDR | 53.522% |
PT Soho Global Health Tbk | 1257.75 Billion IDR | 89.898% |